Articles

1. Lipoprotein(a)

   • K. P. Mellwig
   • A. Vogt

   Editorial Open access 03 April 2019 Pages: 1 - 4

2. Lipoprotein(a) apheresis in patients with peripheral arterial disease: rationale and clinical results

   • Norbert Weiss
   • Ulrich Julius

   OriginalPaper Open access 15 March 2019 Pages: 39 - 44

3. Lipoprotein(a)—antisense therapy

   • Anja Vogt

   OriginalPaper Open access 11 March 2019 Pages: 51 - 56

4. Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region

   • Florian Kronenberg

   ReviewPaper Open access 11 March 2019 Pages: 5 - 12

   

5. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors

   • U. Julius
   • S. Tselmin
   • S. R. Bornstein

   OriginalPaper Open access 05 March 2019 Pages: 45 - 50

   

6. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels

   • V. J. J. Schettler
   • C. L. Neumann
   • Scientific Board of GLAR for the German Apheresis Working Group

   OriginalPaper Open access 05 March 2019 Pages: 33 - 38

   

7. Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism?

   • Alexander Heinrich Nave
   • Arnold von Eckardstein

   OriginalPaper Open access 05 March 2019 Pages: 28 - 32

8. Lipoprotein(a)—an interdisciplinary challenge

   • U. Julius
   • S. Tselmin
   • S. R. Bornstein

   OriginalPaper Open access 05 March 2019 Pages: 20 - 27

   

9. Lipoprotein(a) and mortality—a high risk relationship

   • Reinhard Klingel
   • Andreas Heibges
   • Cordula Fassbender

   OriginalPaper Open access 05 March 2019 Pages: 13 - 19

10. Erratum to: The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on

    • V. J. J. Schettler
    • C. L. Neumann
    • Scientific Board of GLAR for the German Apheresis Working Group

    Erratum 17 July 2017

11. Editorial Lp(a) – the underestimated cardiovascular risk factor

    • Klaus-Peter Mellwig

    Editorial Open access 24 February 2017 Pages: 1 - 1

12. The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on

    • V. J. J. Schettler
    • C. L. Neumann
    • Scientific Board of GLAR for the German Apheresis Working Group

    OriginalPaper Open access 23 February 2017 Pages: 44 - 49

    

13. Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)

    • P. Grützmacher
    • B. Öhm
    • C. Kleinert

    OriginalPaper Open access 23 February 2017 Pages: 22 - 26

14. Lipoprotein (a) and coronary heart disease – is there an efficient secondary prevention?

    • Klaus-Peter Mellwig
    • Dieter Horstkotte
    • Frank van Buuren

    OriginalPaper Open access 23 February 2017 Pages: 18 - 21

    

15. Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease

    • Frank van Buuren
    • Dieter Horstkotte
    • Klaus Peter Mellwig

    OriginalPaper Open access 22 February 2017 Pages: 55 - 59

16. Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies

    • Evelyn Orsó
    • Gerd Schmitz

    OriginalPaper Open access 10 February 2017 Pages: 31 - 37

    

17. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines

    • Reinhard Klingel
    • Andreas Heibges
    • Pro(a)LiFe-Study Group

    OriginalPaper Open access 09 February 2017 Pages: 38 - 43

    

18. Hyperlipoproteinaemia(a) – apheresis and emerging therapies

    • Anja Vogt

    OriginalPaper Open access 09 February 2017 Pages: 12 - 17

19. Lipoprotein(a) in nephrological patients

    • Bernd Hohenstein

    OriginalPaper Open access 08 February 2017 Pages: 27 - 30

    

20. PCSK9 targets important for lipid metabolism

    • Rainer Schulz
    • Klaus-Dieter Schlüter

    OriginalPaper Open access 07 February 2017 Pages: 2 - 11

    

21. Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy – successful treatment with lipoprotein apheresis

    • Franz Heigl
    • Reinhard Hettich
    • Cordula Fassbender

    OriginalPaper Open access 03 February 2017 Pages: 50 - 54

    

22. Rehabilitationsstandards für die Anschlussheilbehandlung und allgemeine Rehabilitation von Patienten mit einem Herzunterstützungssystem (VAD – ventricular assist device)

    • Detlev Willemsen
    • C. Cordes
    • J. Glatz

    OriginalPaper Open access 16 February 2016 Pages: 2 - 49

    

23. Geleitwort zu „Rehabilitationsstandards für die Anschlussheilbehandlung und allgemeine Rehabilitation für Patienten mit einem Herzunterstützungssystem (VAD Ventricular Assist Device)“

    • Hermann Reichenspurner

    Editorial 16 February 2016 Pages: 1 - 1

24. Lipoprotein(a)—clinical aspects and future challenges

    • Bilgen Kurt
    • Muhidien Soufi
    • Juergen R. Schaefer

    OriginalPaper Open access 03 March 2015 Pages: 26 - 32

    

25. Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects

    • Gerd Schmitz
    • Evelyn Orsó

    OriginalPaper Open access 24 February 2015 Pages: 21 - 25

26. Editorial

    • Dieter Horstkotte

    EditorialNotes Open access 19 February 2015 Pages: 1 - 1

27. Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias

    • P. Grützmacher
    • C. Kleinert
    • B. Öhm

    OriginalPaper Open access 17 February 2015 Pages: 2 - 7

28. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease

    • Franz Heigl
    • Reinhard Hettich
    • Reinhard Klingel

    OriginalPaper Open access 12 February 2015 Pages: 8 - 13

    

29. Extrakardiale Manifestation der Lipoprotein(a)-Erhöhung – Gehäuftes Auftreten von peripherer arterieller Verschlusskrankheit und Stenosen der Arteria carotis

    • Frank van Buuren
    • Julia Alexia Sommer
    • Klaus Peter Mellwig

    OriginalPaper Open access 10 February 2015 Pages: 39 - 45

30. Lipoprotein(a) – Einfluss auf die kardiovaskuläre Manifestation

    • K.-P. Mellwig
    • C. Schatton
    • F. van Buuren

    OriginalPaper Open access 10 February 2015 Pages: 33 - 38

    

31. Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels

    • Volker J. J. Schettler
    • Class L. Neumann
    • The German Apheresis Working Group

    OriginalPaper Open access 05 February 2015 Pages: 14 - 20

    

32. Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study

    • Reinhard Klingel
    • Andreas Heibges
    • Cordula Fassbender

    OriginalPaper Open access 03 February 2015 Pages: 46 - 50

    

33. Medikamentöse Therapie bei Frauen – Was gilt es zu beachten?

    • Ursula Ravens

    OriginalPaper 20 March 2013 Pages: 32 - 37

34. Der feine Unterschied – Genderspezifische Aspekte psychosozialer Risikofaktoren und Interventionen bei Patienten mit koronarer Herzkrankheit

    • Alexandra Boese
    • Christoph Herrmann-Lingen

    OriginalPaper 19 March 2013 Pages: 46 - 51

35. Editorial

    • A. Geibel

    EditorialNotes 19 March 2013 Pages: 3 - 5

36. Editorial

    • Georg Ertl

    EditorialNotes 14 March 2013 Pages: 1 - 2

37. Genderspezifische Aspekte in der Sekundärprävention der koronaren Herzerkrankung

    • Oskar Mittag

    OriginalPaper 01 March 2013 Pages: 52 - 56

    

38. Gender aspects in patients with angina and unobstructed coronary arteries

    • Peter Ong
    • Anastasios Athanasiadis
    • Udo Sechtem

    OriginalPaper 19 February 2013 Pages: 25 - 31

    

39. Sex differences and sex hormone effects in long-QT syndrome: what can we learn from rabbit models?

    • Katja E. Odening
    • Manfred Zehender
    • Michael Brunner

    OriginalPaper 19 February 2013 Pages: 14 - 19

    

40. Gender and the risk of stroke in atrial fibrillation: impact of old and new anticoagulation regimens

    • Stavros Z. Apostolakis
    • Stavros V. Konstantinides

    OriginalPaper 16 February 2013 Pages: 38 - 45

41. Risk-treatment paradox in women with symptomatic coronary artery disease

    • Julinda Mehilli
    • Lamin King

    OriginalPaper 16 February 2013 Pages: 20 - 24

    

42. Genes and hormones: sex differences in myocardial hypertrophy

    • Ute Seeland
    • Vera Regitz-Zagrosek

    OriginalPaper 16 February 2013 Pages: 6 - 13

    

43. Editorial

    • Prof. Dr. med. D. Horstkotte

    EditorialNotes Open access 13 June 2012 Pages: 1 - 1

44. Lipid apheresis techniques: current status in Germany

    • Peter Grützmacher
    • Claudius Kleinert

    OriginalPaper Open access 15 May 2012 Pages: 20 - 23

45. Role of lipid apheresis in changing times

    • Peter Schuff-Werner
    • Sebastian Fenger
    • Peter Kohlschein

    OriginalPaper Open access 03 May 2012 Pages: 7 - 14

    

46. HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures

    • Frank van Buuren
    • Sven Kreickmann
    • Klaus Peter Mellwig

    OriginalPaper Open access 20 March 2012 Pages: 24 - 30

    

47. Current view: indications for extracorporeal lipid apheresis treatment

    • Volker Schettler
    • C. L. Neumann
    • The German Apheresis Working Group

    OriginalPaper Open access 20 March 2012 Pages: 15 - 19

48. Lipid apheresis: oxidative stress, rheology, and vasodilatation

    • K.-P. Mellwig
    • E. Pulawski
    • F. van Buuren

    OriginalPaper Open access 10 March 2012 Pages: 45 - 49

49. Fibrinogen/LDL apheresis is a promising rescue therapy for sudden sensorineural hearing loss

    • Martin Canis
    • Franz Heigl
    • Markus Suckfuell

    OriginalPaper Open access 28 February 2012 Pages: 36 - 40

    

50. Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis

    • Nils Ewald
    • Hans-Ulrich Kloer

    OriginalPaper Open access 28 February 2012 Pages: 31 - 35